Professor @Marcrmansour, who works on our project, was also involved in this important study.

Professor Charles Swanton, who works on our project, is among the "Highly Cited Researchers". #HighlyCited2022

The Crick component of DECOD-Ag (led by Charles Swanton) is based on TracerX, and so we will have the opportunity to map neoantigens in this landmark cohort. #TracerX #neoantigens

Excited to present our first DECOD-Ag poster at CICON23! 🎉 Looking forward to sharing our research on predicting neoantigen immunogenicity and connecting with fellow attendees. #CICON23 #neoantigens Great collab with UCL, The Francis Crick Institute, DTU, Weizmann Institute and Achilles Therapeutics.

The Achilles team will be presenting three posters at #CICON23 in Milan 20-23 September, and our CSO, Sergio Quezada, is chairing a roundtable on Targeting Clonal Neoantigens in NSCLC. Full program at cancerimmunotherapyconference.org #Conference #CICON23 #Oncology #Clonals #Neoantigens

Our coordinator Sergio Quezada, as well as Charles Swanton from The Francis Crick Institute who also works on our project, were included in the ‘Highly Cited Researchers List’ for this year. ucl.ac.uk/news/2023/nov/…

Pleased to see the #LouisJeantetPrize in the hands of Charles Swanton who is a member of our DECOD-Ag consortium. The Francis Crick Institute UCL Cancer Institute ucl.ac.uk/news/2024/jan/…

Congratulations to our DECOD-Ag Project Coordinator Sergio Quezada! 👏

In our most recent preprint, we describe the development of a state-of-the-art immunogenicity predictor, laying the necessary foundation for the DECOD-Ag program. UCL Cancer Institute Achilles Therapeutics The Francis Crick Institute Weizmann Institute DTU biorxiv.org/content/10.110…

Congratulations to yardena samuels from Weizmann Institute who has been elected as a President of EACR. She also plays an important role in our DECOD-Ag project. eacr.org/governance/boa…